PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $27,647,950 | -39.6% | 1,657,551 | 0.0% | 1.93% | -49.0% |
Q2 2023 | $45,781,558 | +443.1% | 1,657,551 | +55.5% | 3.80% | +366.2% |
Q2 2022 | $8,430,000 | -50.7% | 1,065,724 | +47.5% | 0.81% | -50.6% |
Q1 2022 | $17,111,000 | +8585.8% | 722,575 | +3875.0% | 1.65% | +9050.0% |
Q4 2021 | $197,000 | +310.4% | 18,178 | -39.4% | 0.02% | +800.0% |
Q3 2021 | $48,000 | – | 30,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |